Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort.
Fiche publication
Date publication
février 2023
Journal
Neurology and therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Pelle J, Briant AR, Branger P, Derache N, Arnaud C, Lebrun-Frenay C, Cohen M, Mondot L, De Seze J, Bigaut K, Collongues N, Kremer L, Ricard D, Bompaire F, Ohlmann C, Sallansonnet-Froment M, Ciron J, Biotti D, Pignolet B, Parienti JJ, Defer G
Lien Pubmed
Résumé
Natalizumab, a therapy for relapsing-remitting multiple sclerosis (RRMS), is associated with a risk of progressive multifocal leukoencephalopathy (PML). Over the last several years, practitioners have used off-label extended interval dosing (EID) of natalizumab to reduce PML risk, despite the absence of a large-scale efficacy evaluation.
Mots clés
Extended interval dosing, Multiple sclerosis, Natalizumab, Real-world evidence
Référence
Neurol Ther. 2023 02 10;: